Traitements futurs de la maladie de Sjögren

Abstract

Sjögren's disease is a systemic autoimmune disease characterized by a triad of symptoms affecting all patients (dryness, pain, and fatigue) and systemic involvement that can affect one-third of patients. The management of patients has long suffered from the lack of effective treatments. However, knowledge of the epidemiology, classification criteria, assessment of systemic activity (ESSDAI) and patient criteria (ESSPRI) has progressed over the last decade. Similarly, advances in the understanding of the pathogenesis of the disease have led to a more targeted therapeutic approach. In this review, we will summarize the advances that have been made in outcome assessment that will shape future trials. We will also provide an overview of promising drugs being evaluated in Sjögren's disease.